Endogenous natural killer cells do not play a role in antitumor effects induced by interleukin-2 in a syngeneic rat colon tumor model

Cancer Immunology Immunotherapy

Volumn 48, Issue 10, 2000, Pages 561-568

  Hagenaars, Martin ^a   Ensink, N Geeske ^a   Eggermont, Alexander M M ^b   Van Der Velde, Edo A ^a   Van De Velde, Cornelis J H ^a   Fleuren, Gert Jan ^a   Kuppen, Peter J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; LYMPHOCYTE DEPLETION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION;

EID: 0033987073     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006674     Document Type: Article

References (35)

1. 1. Abe K, Harada M, Tamada K, Ito O, Li TL, Nomoto K (1998) Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production. Cancer Immunol Immunother 45:225
2. 2. Basse PH, Nannmark U, Johansson BR, Herberman RB, Goldfarb RH (1991) Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natle Cancer Inst 83:944
3. 3. Chambers WH, Vujanovic NL, DeLeo AB, Olszowy MW, Herberman RB, Hiserodt JC (1989) Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 169:1373
4. 4. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M (1997) The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79:2320
5. 5. Egilmez NK, Jong YS, Iwanuma Y, Jacob JS, Santos CA, Chen FA, Mathiowitz E, Bankert RB (1998) Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft SCID mouse model. Cancer Immunol Immunother 46:21
6. 6. Ettinghausen SE, Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 46: 2784
7. + anti-tumor T cells requires tumor expression of cell surface MHC class II molecules. Cell Immunol 178:79
8. 8. Giezeman-Smits KM, Gorter A, Nagelkerke JF, Van Vlierberghe RLP, Van Eendenburg J, Eggermont AMM, Fleuren GJ, Kuppen PJK (1997) Characterization of three new membrane structures on rat NK cells which are involved in activation of the lytic machinery. Immunobiology 197:429
9. 9. Hagenaars M, Zwaveling S, Kuppen PJK, Ensink NG, Eggermont AMM, Hokland ME, Basse PH, Van de Velde CJH, Fleuren GJ, Nannmark U (1998) Characteristics of tumor infiltration by adoptively transferred and endogenous natural killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses. Int J Cancer 78:783
10. 10. Hagenaars M, Ensink NG, Koelemij R, Basse PH, Eggermont AMM, Van de Velde CJH, Fleuren GJ, Kuppen PJK (1998) Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration. Int J Cancer 75:233
11. 11. Hünig T, Wallny HJ, Hartley JK, Lawetzky A, Tiefenthaler G (1989) A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes. J Exp Med 169:73
12. 12. Johansson S, Landström M, Hellstrand K, Henriksson R (1998) The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br J Cancer 77:1213
13. 13. Kos FJ (1998) Regulation of adaptive immunity by natural killer cells. Immunol Res 17:303
14. 14. Kos FJ, Engleman EG (1995) Requirement for natural killer cells in the induction of cytotoxic T cells. J Immunol 155:578
15. 15. Kos FJ, Engleman EG (1996) Immune regulation: a critical link between NK cells and CTL. Immunol Today 17:174
16. 16. Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM (1998) Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res 58:1478
17. 17. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706
18. 18. Maas RA, Dullens HFJ, Van Weering DHJ, De Mik HIJ, Koten J-W, Belger RJ, Den Otter W (1993) Histological analysis of IL-2 induced regression of murine solid SL2-tumors. Biotherapy 6:83
19. 19. Marquet RL, Westbroek DL, Jeekel J (1984) Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 33:689
20. 20. Mather GG, Talcott PA, Exon JH (1994) Characterization of a chemically induced tumor model and the effects of natural killer cell depletion by antiasialo GM-1. Immunobiology 190:333
21. 21. Mulé JJ, Yang JC, Lafreniere R, Shu S, Rosenberg SA (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 139:285
22. 22. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P, Kiessling R (1993) Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610
23. 23. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272
24. 24. Peace DJ, Cheever MA (1989) Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 169:161
25. 25. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169
26. 26. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485
27. 27. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889
28. 28. Rosenberg SA, Yang JC, White DE, Steinberg SM (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2 - identification of the antigens mediating response. Ann Surg 228:307
29. 29. Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA (1986) Eradication of disseminated murine leukemia by treatment with high dose interleukin 2. J Immunol 137:3675
30. 30. Van den Brink MRM, Hunt LE, Hiserodt JC (1990) In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. J Exp Med 171:197
31. 31. Van den Brink MRM, Boggs SS, Herberman RB, Hiserodt JC (1990) The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures. J Exp Med 172:303
32. 32. Weber JS, Jay G, Tanaka K, Rosenberg SA (1987) Immunotherapy of a murine tumor with interleukin 2: increased sensitivity after MHC class I gene transfection. J Exp Med 166:1716
33. 33. Winter BK, Wu S, Nelson AC, Pollack SB (1992) Renal cell carcinoma and natural killer cells: Studies in a novel rat model in vitro and in vivo. Cancer Res 52:6279
34. 34. Wojtowicz-Praga S (1997) Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20:165
35. 35. Yoong KF, Adams DH (1998) Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases. Br J Cancer 77:1072